KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, announced that Steven Katz, Chairman of the Board and President, will present an overview of the Company at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York City. GammaCan’s presentation to the investment community will take place on:
